Ask AI
Bill116th CongressFiled Mar 6, 2019Health
H.R. 1570

Removing Barriers to Colorectal Cancer Screening Act of 2020

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary passed house (Dec 9, 2020)

Removing Barriers to Colorectal Cancer Screening Act of 2020

This bill modifies cost-sharing requirements for colorectal cancer screening tests, and drug manufacturer reporting requirements, under Medicare medical services.

Specifically, the bill waives coinsurance requirements with respect to colorectal cancer screening tests, regardless of the code billed for a resulting diagnosis or procedure. The bill phases in implementation over an eight-year period.

Additionally, manufacturers of covered drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

What just happenedDec 10, 2020

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who’s behind it

Rep. Payne, Donald M., Jr. [D-NJ-10](D-NJ)Sponsor
344 cosponsors215 D129 R
Read on Congress.gov
344cosponsors3committees15actions4related bills4subjects
  1. Dec 10, 2020IntroReferral

    Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Health, Education, Labor, and Pensions Committee
  2. Dec 9, 2020FloorH38800

    The title of the measure was amended. Agreed to without objection.

  3. Dec 9, 2020FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  4. Dec 9, 2020FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7083-7084)

  5. Dec 9, 2020Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

  6. Dec 9, 2020FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 1570.

  7. Dec 9, 2020FloorH30000

    Considered under suspension of the rules. (consideration: CR H7083-7086)

  8. Dec 9, 2020FloorH30300

    Mr. Pallone moved to suspend the rules and pass the bill, as amended.

  9. Mar 8, 2019IntroReferralB00100

    Sponsor introductory remarks on measure. (CR H2608)

  10. Mar 7, 2019Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  11. Mar 6, 2019Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  12. Mar 6, 2019IntroReferralH11100

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Ways and Means Committee
  13. Mar 6, 2019IntroReferralH11100

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Energy and Commerce Committee
  14. Mar 6, 2019IntroReferralIntro-H

    Introduced in House

  15. Mar 6, 2019IntroReferral1000

    Introduced in House

Passed HouseDec 9, 202053

Removing Barriers to Colorectal Cancer Screening Act of 2020

This bill modifies cost-sharing requirements for colorectal cancer screening tests, and drug manufacturer reporting requirements, under Medicare medical services.

Specifically, the bill waives coinsurance requirements with respect to colorectal cancer screening tests, regardless of the code billed for a resulting diagnosis or procedure. The bill phases in implementation over an eight-year period.

Additionally, manufacturers of covered drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

Introduced in HouseMar 6, 2019

Removing Barriers to Colorectal Cancer Screening Act of 2019

This bill waives Medicare coinsurance requirements with respect to colorectal cancer screening tests, regardless of the code billed for a resulting diagnosis or procedure.

Removing Barriers to Colorectal Cancer Screening Act of 2020 — Informed